YALÇIN, Ş. Et Al. 2020. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. BMC CANCER , vol.20, no.1 .

YALÇIN, Ş., DANE, F., Oksuzoglu, B., Ozdemir, N. Y., Isikdogan, A., ÖZKAN, M., ... Demirag, G. G.(2020). Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. BMC CANCER , vol.20, no.1.

YALÇIN, ŞUAYİB Et Al. "Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study," BMC CANCER , vol.20, no.1, 2020

YALÇIN, ŞUAYİB Et Al. "Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study." BMC CANCER , vol.20, no.1, 2020

YALÇIN, Ş. Et Al. (2020) . "Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study." BMC CANCER , vol.20, no.1.

@article{article, author={ŞUAYİB YALÇIN Et Al. }, title={Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study}, journal={BMC CANCER}, year=2020}